Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?

Henri Boulanger; Rafik Mansouri; Jean François Gautier; and Denis Glotz

首页> 外文期刊>Nephrology Dialysis Transplantation >Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?

【24h】

Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?

机译：过氧化物酶体增殖物激活受体在糖尿病和非糖尿病肾病中是否是新的治疗靶标？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Nephrology Dialysis Transplantation》 |2006年第10期|2696-2702|共7页
作者
Henri Boulanger; Rafik Mansouri; Jean François Gautier; and Denis Glotz;
展开▼
作者单位

Department of Nephrology and Transplantation and;

Department of Diabetes and Endocrinology Saint-Louis Hospital Paris France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population [J] . B. Fagerberg, S. Edwards, T. Halmos, Diabetologia . 2005,第9期

机译：Tesaglitazar，一种新型的双重过氧化物酶体增殖物激活受体α/γ激动剂，可剂量依赖性地改善非糖尿病人群中与胰岛素抵抗相关的代谢异常
2. The Gly482Ser Variant in the Peroxisome Proliferator-Activated Receptor gamma Coactivator-1 is not Associated with Diabetes-Related Traits in Non-Diabetic German and Dutch Populations. [J] . Stumvoll M, Fritsche A, THart LM, Experimental and clinical endocrinology and diabetes: Official journal, German Society of Endocrinology [and] German Diabetes Association . 2004,第5期

机译：在非糖尿病的德国人和荷兰人中，过氧化物酶体增殖物激活的受体γCoactivator-1的Gly482Ser变异与糖尿病相关的性状无关。
3. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. [J] . Sidhu JS, Cowan D, Kaski JC Journal of the American College of Cardiology . 2003,第10期

机译：罗格列酮（一种过氧化物酶体增殖物激活的受体-γ激动剂）对非糖尿病性冠状动脉疾病患者内皮细胞激活，C反应蛋白和纤维蛋白原水平的影响。
4. THE RENIN-ANGIOTENSIN SYSTEM AND ADVANCED GLYCATION END-PRODUCTS IN DIABETIC NEPHROPATHY HOW IMPORTANT ARE THESE PATHWAYS AS THERAPEUTIC TARGETS? [C] . K.C. Sourris, J.M. Forbes International Symposium on the Maillard Reaction . 2010

机译：糖尿病肾病的肾素 - 血管紧张素系统和先进的糖糖末端产物是治疗靶标的这些途径有多重要？
5. Peroxisome Proliferator-activated Receptor Gamma Inhibition as a Novel Therapeutic Strategy in Prostate Cancer [D] . Elix, Catherine. 2020

机译：过氧化物体增殖物激活的受体γ抑制作是前列腺癌的新疗法策略
6. Trigonelline reduced diabetic nephropathy and insulin resistance in type 2 diabetic rats through peroxisome proliferator-activated receptor-γ [O] . Yinyan Li, Qaobei Li, Chunyan Wang, -1

机译：Trigonelline通过过氧化物酶体增殖物激活受体-γ减轻2型糖尿病大鼠的糖尿病肾病和胰岛素抵抗
7. Peroxisome Proliferator-Activated Receptors in Diabetic Nephropathy [O] . Kume, Shinji, Uzu, Takashi, Isshiki, Keiji, 2008

机译：糖尿病肾病中过氧化物酶体增殖物激活的受体

Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?

著录项

相似文献

相关主题

期刊订阅